I agree, you only have to look at Blincyto history of approval as another example. I have to say, AMGEN did a great job in getting this drug approved so quickly.
Development timeline for Blincyto
The drug (originally known as MT103) was developed by a German-American company Micromet, Inc. in cooperation with Lonza; In 2012, Micromet was purchased by Amgen, which furthered the drug's clinical trials.https://www.drugs.com/history/blincyto.html and https://en.wikipedia.org/wiki/Blinatumomab
Cost
When blinatumomab was approved, Amgen announced that the price for the drug would be US$178,000 per year, which made it the most expensive cancer drug on the market. Merck's pembrolizumab was priced at US$150,000 per year when it launched (in September 2014).[15] At the time of initial approval, only about 1,000 patients in the US had an indication for blinatumomab.
- Forums
- ASX - By Stock
- IMU
- Media Thread
Media Thread, page-14635
-
- There are more pages in this discussion • 1,202 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.3¢ |
Change
0.004(8.16%) |
Mkt cap ! $394.1M |
Open | High | Low | Value | Volume |
4.9¢ | 5.5¢ | 4.8¢ | $1.798M | 35.09M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 2193808 | 5.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.3¢ | 605064 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 2192847 | 0.052 |
7 | 1399145 | 0.051 |
12 | 1193048 | 0.050 |
20 | 6833876 | 0.049 |
66 | 9686793 | 0.048 |
Price($) | Vol. | No. |
---|---|---|
0.053 | 605064 | 3 |
0.054 | 1194213 | 11 |
0.055 | 6979391 | 12 |
0.056 | 1271350 | 12 |
0.057 | 1597104 | 6 |
Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online